NEWSTIER

Court Grants FTC's Request to Block Henkel's $725M Deal for Liquid Nails | A court granted the Federal Trade Commission's request to block Henkel from acquiring Liquid Nails, a rival of its construction adhesive brand Loctite. The U.S. District Court for the Southern District of New York granted th…

*Swiss Water Decaff Coffee: TSX Approves Share Buyback Under NCIB | (MORE TO FOLLOW) Dow Jones Newswires 08-17-26 1709ET Copyright (c) 2026 Dow Jones & Company, Inc.

*FTC: Court Grants Request for Permanent Injunction to Block Henkel's Proposed Acquisition of Liquid Nails From American Industrial Partners | (MORE TO FOLLOW) Dow Jones Newswires 08-17-26 1628ET Copyright (c) 2026 Dow Jones & Company, Inc.

XP's Board Of Directors Approves The Cancellation Of Existing Treasury Class A Shares Held By The Company; Total Share Count Went From 520,292,030 To 508,500,275 After Cancellation | 4:08 PM EDT, August 17, 2026 (Benzinga Newswire) XP Inc. (NASDAQ:XP), announced today that its board of directors ha…

Amylyx Pharmaceuticals shares are trading higher after the company announced it will reveal its topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026. |

Amylyx Pharmaceuticals To Announce Phase 3 LUCIDITY Trial Topline Results For Avexitide In Post-Bariatric Hypoglycemia On August 18 At 8:00 a.m. ET | 4:01 PM EDT, August 17, 2026 (Benzinga Newswire) Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will announce topline results…

Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 | CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will announce topline results from…

FTC Release: Statement on FTC Win Blocking Loctite, Liquid Nails Construction Adhesive Merger | The Federal Trade Commission secured an important victory in the fight to lower the cost of housing construction materials for Americans by preventing German multinational Henkel AG & Co. KGaA (Henkel),…

Nasdaq Discussing With Regulators To Roll Out ~23-Hour Trading; Expected To Take Place Dec. 6 | 3:59 PM EDT, August 17, 2026 (Benzinga Newswire) https://www.nasdaq.com/docs/nasdaq-global-trading-hours-faqs Write to Benzinga at editorial@benzinga.com

ExxonMobil Awards ~$1.1B Contracts For Upstream Equipment Supporting Rovuma LNG Phase 1 Development In Cabo Delgado | 3:47 PM EDT, August 17, 2026 (Benzinga Newswire) https://corporate.exxonmobil.com/locations/mozambique/mozambique-newsroom/exxonmobil-mozambique-and-area-4-coventurers-award-over-1-…

FTC Release: Founders of Celsius Network Ordered to Pay $16.5 Million to Resolve FTC Charges | Proposed orders also ban defendants from marketing or selling products or services that can be used to deposit or withdraw assets Alexander Mashinsky, the former CEO of cryptocurrency platform Celsius Net…

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™ | WASHINGTON--(BUSINESS WIRE)-- Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of…

'Trump approval falls to 33%, lowest of his presidency, Reuters/Ipsos poll finds' - Reuters | 3:05 PM EDT, August 17, 2026 (Benzinga Newswire) https://www.reuters.com/world/us/trump-approval-falls-33-lowest-his-presidency-reutersipsos-poll-finds-2026-08-17/ Write to Benzinga at editorial@benzinga.c…

EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction. -- Barrons.com | EyePoint's experimental treatment for an advanced eye disease yielded what management called "clinically meaningful results" in a late-stage trial. Shares were pacing toward their worst day on record an…

Update: argenx Shares Rise After Autoimmune Myositis Drug Meets Main Goal in Phase 3 Study | 02:30 PM EDT, 08/17/2026 (MT Newswires) -- (Updates with reporting date in the first paragraph, and the latest stock move in the headline and first paragraph) argenx (ARGX) shares rose more than 16% in Mond…

Update: Almonty Industries Shares Rise After Board Approves $300 Million Buyback Plan | 02:21 PM EDT, 08/17/2026 (MT Newswires) -- (Updates with the latest stock movement in the first paragraph and headline.) Almonty Industries (ALM) shares were up over 7% in Monday trading after the company said i…

FTC Release: FTC Takes Action Against Elite Events for Bypassing Ticket Purchase Limits in Violation of Better Online Ticket Sales Act | Proposed order settling FTC allegations will require company and its executives to pay $300,000 and ban them from using unlawful tactics to bypass ticket purchase…

FTC Release: FTC Takes Action Against Elite Events for Bypassing Ticket Purchase Limits in Violation of Better Online Ticket Sales Act | Proposed order settling FTC allegations will require company and its executives to pay $300,000 and ban them from using unlawful tactics to bypass ticket purchase…

EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction. -- Barrons.com | EyePoint's experimental treatment for an advanced eye disease yielded what management called "clinically meaningful results" in a late-stage trial. Shares were pacing toward their worst day on record an…

Lupin Announces Approval from U.S. FDA for Pitolisant Tablets | MUMBAI, India and NAPLES, Fla., Aug. 17, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval…

FTC Release: FTC Stops Sprawling Credit Repair Scheme that Scammed Consumers Out of Nearly $200 Million | Scheme allegedly deceptively posed as debt collectors and creditors, used false and misleading promises to collect illegal upfront fees and recurring charges At the request of the Federal Trade…

FTC Release: Bill Payment Firm Doxo to Pay $2.1 Million to Settle FTC Allegations It Deceived Consumers and Charged Them Add-On Fees | Online bill payment firm Doxo will pay $2.1 million to settle Federal Trade Commission allegations that the company and two of its co-founders used misleading searc…

Shares of crypto-linked companies are trading higher amid a rise in Bitcoin. Catalysts may include the Trump family's crypto business, World Liberty Financial, receiving conditional approval to establish a bank, and expectations that President Trump will attend a meeting with crypto and prediction…

EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction. | EyePoint's experimental treatment for an advanced eye disease yielded what management called "clinically meaningful results" in a late-stage trial. Shares were pacing toward their worst day on record anyway. The small…

Acurx Pharmaceuticals shares are trading higher after the company announced that the FDA has conditionally accepted the proposed proprietary, or brand name, CIFBEZY for ibezapolstat. |

iGov Technologies Selected to Advance to Phase 2 of U.S. Marine Corps EWGIR Prototype Program | TAMPA, Fla.--(BUSINESS WIRE)-- iGov Technologies, Inc., a leading provider of advanced federal tactical communications solutions, has been selected to advance to Phase 2 of the U.S. Marine Corps’ Electro…

Faeth Therapeutics Shares Rise on FDA Fast-Track Designation for Cancer Treatment | Faeth Therapeutics shares rose Monday morning after the clinical-stage oncology company said the Food and Drug Administration granted fast-track designation to its experimental cancer treatment. Shares were recently…

Argenx’s Next Blockbuster? Stock Jumps 12% After Phase 3 Myositis Trial Hits Key Goal | 9:22 AM EDT, August 17, 2026 (Benzinga Newswire) Argenx SE (NASDAQ:ARGX) stock jumped about 12% in Monday’s premarket trading after the company reported positive topline results from its Phase 3 ALKIVIA study. T…

MYND.AI, INC. RECEIVES NYSE AMERICAN APPROVAL OF COMPLIANCE PLAN AND EXTENSION THROUGH DECEMBER 2027 | NYSE American Acceptance Provides Continued Listing While Company Executes Strategic Growth and Balance Sheet Initiatives ALPHARETTA, Ga., Aug. 17, 2026 /PRNewswire/ -- Mynd.ai, Inc. ("Mynd" or th…

Galmed Pharmaceuticals Announces Results From Pre-Clinical Study Of Combination Of Aramchol And Xtandi For Prostatic Cancer; New Data Demonstrated That A Combination Of Aramchol With Enzalutamide Resulted In Three- To Four-Fold Increase In Cell Death Compared With Enzalutamide As A Single Agent | 9…

Leal Therapeutics Announces $30 Million Series A Extension and Initiation of Phase 1b/2a Clinical Trial of LTX-001 in Schizophrenia | Phase 1b/2a clinical trial assessing safety and efficacy of LTX-001 in adults with schizophrenia initiated Financing advances LTX-001 through initial readout from Ph…

U.S. Food and Drug Administration Approves an Autoinjector Version of LEROCHOL® (lerodalcibep-liga) and Updated Indication | LEROCHOL is the first and only PCSK9 inhibitor with once-monthly, single-injection dose self-administered by patients with room temperature storage up to three months now app…

Connext Completes Enrollment in Phase 2 Trial of CNT201 in Dupuytren's Contracture | - All 56 planned participants enrolled approximately five months after first patient dosing - Topline Phase 2 data expected in late 2026 - Positive data could support expansion of CNT201 into Peyronie's disease and…

Artelo Biosciences Says USPTO Issues Notice Of Allowance For U.S. Patent Application Covering Intended Commercial Formulation Of ART27.13, Peripherally Selective Cannabinoid Agonist Currently In Phase 2 Studies | 8:56 AM EDT, August 17, 2026 (Benzinga Newswire) The Patent Claims are for the Intende…

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies | The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 S…

EyePoint shares are trading lower after the company announced topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU. The primary endpoint of change from baseline in best corrected visual acuity versus 2 mg aflibercept on-label control was not achieved in the full dataset…

UroGen Pharma Submits US FDA New Drug Application for UGN-103 in Recurrent Bladder Cancer | 08:42 AM EDT, 08/17/2026 (MT Newswires) -- UroGen Pharma (URGN) submitted a new drug application to the US Food and Drug Administration for UGN-103 to treat adults with recurrent low-grade intermediate-risk…

WhiteWater-led venture approves Permian-to-Texas gas pipeline project |

TOMI Environmental Solutions Announces Ireland Approval Of BIT Solution Under EU Biocidal Products Regulation, Extending Authorizations To 11 European Markets |

HUTCHMED shares are trading higher after the company announced high-level results from the SAFFRON Phase III trial. |

TOMI Secures Critical Ireland Market Approval, Strengthening SteraMist's Position Across the European Union | FREDERICK, Md., Aug. 17, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced today…

VivoPower Board Approves Creation Of Separate, Independent Singapore-Based AI Infrastructure Firm | 8:17 AM EDT, August 17, 2026 (Benzinga Newswire) VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructu…

VivoPower Approves Independent Listing of 2.2GW Non-Nordic AI Infrastructure Platform, Transferring Capital Expenditure Requirements Whilst Retaining De Facto Control | VivoPower team has assembled a non-Nordic portfolio and pipeline in excess of 2.2GW across the GCC and ASEAN regions through sover…

FDA Conditionally Accepts Acurx Pharmaceuticals' Brand Name CIFBEZY for Ibezapolstat | 8:09 AM EDT, August 17, 2026 (Benzinga Newswire) The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO These in…

Almonty Industries Approves $300 Million Buyback Program | 08:07 AM EDT, 08/17/2026 (MT Newswires) -- Almonty Industries (ALM) said Monday that its board of directors has approved a new share repurchase program of up to $300 million. The company said the program allows the purchase of up to 14.4 mi…

UroGen Pharma Submits NDA To FDA For Its Investigational Drug UGN-103 For Intravesical Solution | 8:05 AM EDT, August 17, 2026 (Benzinga Newswire) UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty…

Faeth Therapeutics Gets US FDA Fast Track Designation for Endometrial Cancer Drug Combination | 08:01 AM EDT, 08/17/2026 (MT Newswires) -- Faeth Therapeutics (FTH) has received fast track designation from the US Food and Drug Administration for the combination of sapanisertib and serabelisib with p…

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat | The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO These in…

OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors | — ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous formulation designed to provide gradual syst…

AI Financial Corporation Congratulates World Liberty Financial on OCC Preliminary Conditional Approval for National Trust Bank | LAS VEGAS, NV / ACCESS Newswire / August 17, 2026 / AI Financial Corporation (NASDAQ:AIFC)(FRA:5AR1) ("AiFi" or the "Company"), today congratulated World Liberty Financia…

EyePoint Misses Primary Goal in Phase 3 Wet AMD Trial of Duravyu; Shares Drop Pre-Bell | 07:57 AM EDT, 08/17/2026 (MT Newswires) -- EyePoint (EYPT) said Monday its Phase 3 Lugano trial testing Duravyu in patients with wet age-related macular degeneration failed to achieve its primary endpoint. The…

Mesoblast shares are trading higher after the company announced it completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain. |

United Therapeutics Completes Enrollment in Phase 3 PPF Trial of Tyvaso | 07:41 AM EDT, 08/17/2026 (MT Newswires) -- United Therapeutics (UTHR) said Monday that its Phase 3 TETON-PPF study evaluating nebulized Tyvaso in patients with progressive pulmonary fibrosis has fully enrolled 754 participant…

AstraZeneca And Daiichi Sankyo Report DESTINY‑Lung04 Phase III Trial Results; ENHERTU Improves Progression‑Free Survival Versus Standard Of Care In HER2‑Mutant NSCLC | 7:39 AM EDT, August 17, 2026 (Benzinga Newswire) AstraZeneca and Daiichi Sankyo’s ENHERTU is the first and only HER2-directed medic…

Castle Biosciences Gets Approval for Dual Listing on Nasdaq Texas | 07:38 AM EDT, 08/17/2026 (MT Newswires) -- Castle Biosciences (CSTL) has received approval for the dual listing of its common stock on Nasdaq Texas, in addition to its primary listing on the Nasdaq Global Market, the company said M…

Radiopharm Theranostics Schedules An FDA End-Of-Phase 2 For October 1, 2026, To Align On The Design Of A Pivotal Phase 3 Trial To Evaluate RAD101 In Patients With Suspected Recurrence Of Brain Metastases Following Radiotherapy | 7:36 AM EDT, August 17, 2026 (Benzinga Newswire) RAD101 is the Company…

Almonty Industries Board Approves $300M Share Repurchase Program | 7:35 AM EDT, August 17, 2026 (Benzinga Newswire) Repurchase Program Aims to Create Shareholder Value by Capturing Disconnect Between Share Price and Value of Almonty’s Strategic Tungsten Assets and Growth Prospects Ahead of Initial…

argenx shares are trading higher after the company announced topline results from the ALKIVIA Phase 3 study met its primary endpoint. |

Faeth Therapeutics Says FDA Grants Fast Track Designation To Combination Of Sapanisertib And Serabelisib With Paclitaxel For Treatment Of Patients With Endometrial Cancer | 7:33 AM EDT, August 17, 2026 (Benzinga Newswire) — Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in…

Advasa Holdings, Inc. Announces Effectiveness of Registration Statement and Approval to List Common Stock on the Nasdaq Global Market | Common Stock Expected to Begin Trading on or about August 18, 2026 Under the Ticker Symbol "ADBT" TOKYO and NEW YORK, Aug. 17, 2026 /PRNewswire/ -- Advasa Holdings…

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases | RAD 101 Phase 2b trial demonstrated 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial's primary endpoint End-of-Phase 2 meeting with t…

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer | — Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in combination with paclitaxel for the treatment of patients with advanced or rec…

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial | AstraZeneca and Daiichi Sankyo’s ENHERTU is the f…

Advasa Holdings, Inc. Announces Effectiveness of Registration Statement and Approval to List Common Stock on the Nasdaq Global Market | TOKYO and NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Advasa Holdings, Inc. (“ADVASA” or the “Company”), a fintech payment holding company providing Earned Wage Ac…

Advasa Holdings, Inc. Announces Effectiveness of Registration Statement and Approval to List Common Stock on the Nasdaq Global Market | Common Stock Expected to Begin Trading on or about August 18, 2026 Under the Ticker Symbol “ADBT” TOKYO & NEW YORK--(BUSINESS WIRE)-- Advasa Holdings, Inc. (“ADVAS…

Update: Apple Changes App Tracking Rules Following German Competition Authority Review | 07:28 AM EDT, 08/17/2026 (MT Newswires) -- (Updates to include additional details in the third paragraph) Apple (AAPL) will modify its App Tracking Transparency Framework consent prompts for personalized advert…

AstraZeneca And HUTCHMED’s Savolitinib, In Combination With TAGRISSO, Delivers Significant Survival Benefits In SAFFRON Phase III EGFRm Lung Cancer Trial | 7:10 AM EDT, August 17, 2026 (Benzinga Newswire) First global Phase III trial to show significant progression-free and overall survival benefit…

Pulsenmore Receives Second AI Grant Within One Month As Israel Innovation Authority Approves $1.27M For SmartScan AI |

Castle Biosciences Approved For Dual Listing On Nasdaq Texas While Maintaining Primary Listing On Nasdaq Global Market |

EyePoint Announces Topline Results From LUGANO, First Pivotal Phase 3 Clinical Trial For DURAVYU For Treatment Of Wet Age-Related Macular Degeneration | 7:04 AM EDT, August 17, 2026 (Benzinga Newswire) – DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad ho…

Press Release: Pulsenmore Receives Second AI Grant Within One Month: Israel Innovation Authority Approves $1.27 Million for SmartScan AI Program | The new grant brings the total AI grants approved for Pulsenmore over the past month to approximately $1.6 million, supporting two programs with a combi…

Pulsenmore Receives Second AI Grant Within One Month: Israel Innovation Authority Approves $1.27 Million for SmartScan AI Program | The new grant brings the total AI grants approved for Pulsenmore over the past month to approximately $1.6 million, supporting two programs with a combined scope of ap…

Castle Biosciences Approved for Dual Listing on Nasdaq Texas | FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been approved to have its common stock d…

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD | – DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experien…

Market Chatter: Apple Changes App Tracking Rules Following German Competition Authority Review | 06:47 AM EDT, 08/17/2026 (MT Newswires) -- Apple (AAPL) will modify its App Tracking Transparency Framework consent prompts for personalized advertising on iPhones and iPads following a German antitrust…

Ascelia Pharma Announces FDA Has Scheduled Type A Meeting for Orviglance NDA on September 9, 2026 | MALMÖ, SE / ACCESS Newswire / August 17, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotech company focused on improving the lives of people living with rare cancer conditions, today announced that…

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis | Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed earl…

Update: argenx Says Autoimmune Myositis Drug Meets Main Goal in Phase 3 Study | 05:01 AM EDT, 08/17/2026 (MT Newswires) -- (Updates with reporting date in the first paragraph and the latest stock move in the last paragraph) argenx (ARGX) said Monday a phase 3 study evaluating its experimental drug,…

argenx Says Autoimmune Myositis Drug Meets Main Goal in Phase 3 Study | 04:25 AM EDT, 08/17/2026 (MT Newswires) -- argenx (ARGX) said a phase 3 study evaluating its experimental drug, Vyvgart Hytrulo, in adults with autoimmune myositis met main goal. The company said the patients treated with the d…

Mesoblast Completes Patient Treatment in Phase 3 Trial of Chronic Low Back Pain | 04:13 AM EDT, 08/17/2026 (MT Newswires) -- Mesoblast (MESO) said Sunday it has completed patient treatment in a phase 3 trial of its experimental rexlemestrocel-L for chronic low back pain associated with degenerative…